Cabozantinib Combined With PD-1 and CTLA-4 Inhibition in Metastatic Soft Tissue Sarcoma

Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2021
The hypothesis of this study is that the response rate of soft tissue sarcoma will be improved with the addition of PD-1 and CTLA-4 inhibition to cabozantinib, and that cabozantinib priming will increase the response to nivolumab and ipilimumab.
Epistemonikos ID: 2d5dc4a52eaf39e6bf79f9c5f4715fb78a0d36e8
First added on: May 07, 2024